These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 11267163

  • 1. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F.
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract] [Full Text] [Related]

  • 2. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L, Henriques AC, Dias L, Sarmento AM, Pereira MC, Guimarães S.
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract] [Full Text] [Related]

  • 3. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J.
    Transplant Proc; 2001 Dec; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract] [Full Text] [Related]

  • 4. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 5. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber AO.
    Transplant Proc; 2001 Apr 27; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract] [Full Text] [Related]

  • 6. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B.
    Transplant Proc; 1999 Dec 27; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract] [Full Text] [Related]

  • 7. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep 27; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 8. New immunosuppressive agents in pediatric renal transplantation.
    Ettenger RB.
    Transplant Proc; 1998 Aug 27; 30(5):1956-8. PubMed ID: 9723350
    [No Abstract] [Full Text] [Related]

  • 9. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW, Ciancio C, Blomberg BB, Rosen A, Suzart K, Roth D, Kupin W, Esquenazi V, Miller J.
    Transplant Proc; 2002 Aug 27; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract] [Full Text] [Related]

  • 10. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F.
    Transplant Proc; 1999 Sep 27; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract] [Full Text] [Related]

  • 11. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Sep 27; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 12. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 27; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR.
    Transplant Proc; 2002 Aug 27; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract] [Full Text] [Related]

  • 14. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Aug 27; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 15. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.
    Am J Transplant; 2009 Aug 27; 9(8):1876-85. PubMed ID: 19563339
    [Abstract] [Full Text] [Related]

  • 16. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.
    Transplant Proc; 2001 Aug 27; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract] [Full Text] [Related]

  • 17. Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation.
    Schnitzler MA, Woodward RS, Lowell JA, Singer GG, Brennan DC.
    Transplant Proc; 1999 May 27; 31(3B Suppl):19S-21S. PubMed ID: 10330963
    [No Abstract] [Full Text] [Related]

  • 18. Daclizumab.
    Mottershead M, Neuberger J.
    Expert Opin Biol Ther; 2007 Oct 27; 7(10):1583-96. PubMed ID: 17916050
    [Abstract] [Full Text] [Related]

  • 19. Results of renal transplantation with different immunosuppressive regimens.
    Folkmane I, Bicans J, Chapenko S, Murovska M, Rosentals R.
    Transplant Proc; 2002 Mar 27; 34(2):558-9. PubMed ID: 12009623
    [No Abstract] [Full Text] [Related]

  • 20. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB.
    N Engl J Med; 2007 Dec 20; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.